Skip to Main Content

++

REFERENCES

++

Chapter 1

1.  +
Overington  JP, Al-Lazikani  B, Hopkins  AL: How many drug targets are there? Nat Rev Drug Discov 5(12):993–6, 2006.
CrossRef  [PubMed: 17139284]
2.  +
von Zastrow  M, von Zastrow  M: Chapter 2. Drug receptors & pharmacodynamics, in Katzung  BG, Masters  SB, Trevor  AJ (eds). Basic & Clinical Pharmacology, 12th ed. New York: McGraw-Hill, 2012. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=55820126. Accessed August 1 , 2013.
3.  +
Charmot, D: Non-systemic drugs: A critical review. Curr Pharm Des 18(10):1434–45, 2012.
CrossRef  [PubMed: 22300258]
4.  +
Shargel  L, Wu-Pong  S, Yu  AB: Chapter 14. Biopharmaceutic considerations in drug product design and in vitro drug product performance, in Shargel  L, Wu-Pong  S, AB  Yu (eds). Applied Biopharmaceutics & Pharmacokinetics, 6th ed. New York: McGraw-Hill, 2012. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=56604846. Accessed August 1 , 2013.
5.  +
Giacomini  KM, Sugiyama  Y: Chapter 5. Membrane transporters and drug response, in Brunton  LL, Chabner  BA, Knollmann  BC (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. New York: McGraw-Hill, 2011. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=16658945. Accessed August 1 , 2013.
6.  +
Buxton  IL, Benet  LZ: Chapter 2. Pharmacokinetics: The dynamics of drug absorption, distribution, metabolism, and elimination, in Brunton  LL, Chabner  BA, Knollmann  BC (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. New York: McGraw-Hill, 2011. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=16658120. Accessed August 1 , 2013.
7.  +
Zamek-Gliszczynski  MJ, Hoffmaster  KA, Nezasa  K, Tallman  MN, Brouwer  KL: Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27(5):447–86, 2006. Epub February 10 , 2006.
CrossRef  [PubMed: 16472997]
8.  +
Shargel  L, Wu-Pong  S, Yu  AB: Chapter 10. Physiologic drug distribution and protein binding, in Shargel  L, Wu-Pong  S, AB  Yu (eds). Applied Biopharmaceutics & Pharmacokinetics, 6th ed. New York: McGraw-Hill, 2012. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=56603200. Accessed August 1 , 2013.
9.  +
Luc EC De  Baerdemaeker, LEC, Mortier, EP, Struys  MMRF: Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain 4(5):152–5, 2004.
CrossRef
10.  +
Prouillac  C, Lecoeur  S: The role of the placenta in fetal exposure to xenobiotics: Importance of membrane transporters and human models for transfer studies. Drug Metab Dispos 38(10):1623–35, 2010.
CrossRef  [PubMed: 20606001]
11.  +
Correia  MA: Chapter 4. Drug biotransformation, in Katzung  BG, Masters  SB, Trevor  AJ (eds). Basic & Clinical Pharmacology, 12th ed. New York: McGraw-Hill, 2012. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=55820515. Accessed August 1 , 2013.
12.  +
Gonzalez  FJ, Coughtrie  M, Tukey  RH: Chapter 6. Drug metabolism, in LL Brunton, Chabner  BA, Knollmann  BC (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. New York: McGraw-Hill, 2011. www.accesspharmacy.com.lp.hscl.ufl.edu/content.aspx?aID=16659426. Accessed August 1 , 2013.
13.  +
Shargel  L, Wu-Pong  S, Yu  AB: Chapter 11. Drug elimination and hepatic clearance, in Shargel  L, ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.